Welcome to the international HTA database

Showing [20046 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
1993	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	Telemedicine in the management of neurosurgical emergencies in Paris (systematic review, primary research, expert panel, working group)
1997	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	Telemedicine in the management of neurosurgical emergencies in Paris (systematic review, primary research, expert panel, working group)
1998	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	Telemedicine in the management of neurosurgical emergencies in Paris (systematic review, primary research, expert panel)
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Telemetry devices to monitor cardiac patients: a review of the safety and guidelines
2007	Institute of Health Economics (IHE)	Teleoncology: applications and associated benefits for the adult population
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Telepathology: a review of the clinical effectiveness, cost-effectiveness, and guidelines
2008	HAYES, Inc.	Telephone intervention for depression
2008	HAYES, Inc.	Telephone monitoring for depression
1998	Alberta Heritage Foundation for Medical Research (AHFMR)	Telephone nurse triage services
2003	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Telephone triage services: systematic review and a survey of Canadian call centre programs
2009	HAYES, Inc.	Teleradiology for neurosurgical consultations
2011	HAYES, Inc.	Telerehabilitation after stroke
2012	HAYES, Inc.	Telerehabilitation for musculoskeletal conditions, neuromuscular conditions, and mobility impairment
1997	Danish Institute for Health Services Research (DSI)	Telescopic surgery in the abdomen. Consensus report
2012	Adelaide Health Technology Assessment (AHTA)	Television marketing of unhealthy food and beverages to children in Australia: a review of published evidence from 2009
2001	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Telithromycin
2007	NIHR Horizon Scanning Centre (NIHR HSC)	Temozolomide (Temodal) for advanced metastatic melanoma: horizon scanning technology briefing
2017	Agency for Care Effectiveness (ACE)	Temozolomide for the treatment of malignant glioma
2006	VA Technology Assessment Program (VATAP)	Temporal artery thermometry in the post-operative setting
2018	NIHR Health Technology Assessment programme	Temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations: FAST
2006	HAYES, Inc.	Temporomandibular joint (TMJ) reconstruction with the patient-fitted TMJ reconstruction prosthesis (TMJ Concepts)
2005	Adelaide Health Technology Assessment (AHTA)	Temptouch (R): infrared thermometer device for prevention of foot ulcers in people with diabetes
2006	NIHR Horizon Scanning Centre (NIHR HSC)	Temsirolimus (Torisel) for advanced or metastatic renal cell carcinoma: horizon scanning technology briefing
2008	NIHR Horizon Scanning Centre (NIHR HSC)	Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory
2005	NIHR Horizon Scanning Centre (NIHR HSC)	Temsirolimus for locally advanced and metastatic breast cancer - horizon scanning review
2005	NIHR Horizon Scanning Centre (NIHR HSC)	Temsirolimus for metastatic renal cell carcinoma (stage IV) - horizon scanning review
2010	National Institute for Health and Clinical Excellence (NICE)	Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal)
2001	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Tenecteplase: single-bolus thrombolytic therapy for acute myocardial infarction
2021	Agency for Care Effectiveness (ACE)	Tenofovir alafenamide for treating chronic hepatitis B infection
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Tenofovir alafenamide monotherapy for hepatitis B
2009	National Institute for Health and Clinical Excellence (NICE)	Tenofovir disoproxil for the treatment of chronic hepatitis B
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Tenofovir disoproxil fumarate (Viread®)
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Tenofovir disoproxil fumarate (Viread®)
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Tenofovir disoproxil fumarate (Viread®)
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Tenofovir disoproxil fumarate (Viread®)
2008	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Tenofovir disoproxil fumarate (Viread®) for the treatment of hepatitis B
2007	NIHR Horizon Scanning Centre (NIHR HSC)	Tenofovir disoproxil fumarate for hepatitis B: horizon scanning technology briefing
2010	NIHR Health Technology Assessment programme	Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection
2000	NIHR Horizon Scanning Centre (NIHR HSC)	Tension free vaginal tape for urinary incontinence - horizon scanning review
2002	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Tension-free vaginal tape (TVT) for urinary incontinence
2008	Haute Autorite de sante (HAS)	Tension-free vaginal tape and women stress incontinence
2004	Medical Advisory Secretariat (MAS)	Tension-free vaginal tape for stress urinary incontinence
2005	HAYES, Inc.	Tension-free vaginal tape procedure for treatment of female stress urinary incontinence
2002	HAYES, Inc.	Tension-free vaginal tape procedure for treatment of female stress urinary incontinence
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Terahertz intraoperative breast cancer probe
2011	Agency for Healthcare Research and Quality (AHRQ)	Terbutaline pump for the prevention of preterm birth
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Teriflunomide for relapsing multiple sclerosis (MS) - first line
2013	NIHR Health Technology Assessment programme	Teriflunomide for treating relapsing forms of multiple sclerosis
2004	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Teriparatide
2008	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Teriparatide (Forsteo®) for the treatment of osteoporosis in men at increased risk of fracture
2006	Canadian Agency for Drugs and Technologies in Health (CADTH)	Teriparatide and bisphosphonates for treatment of osteoporosis in women: a clinical and economic analysis
2001	NIHR Horizon Scanning Centre (NIHR HSC)	Teriparatide for osteoporosis - horizon scanning review
2003	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Teriparatide for the treatment of osteoporosis
2001	Israel Center for Technology Assessment in Health Care (ICTAHC)	Terror and medicine - the challenge
2003	Israel Center for Technology Assessment in Health Care (ICTAHC)	Terror and Medicine (New book written by over 100 medical experts in Israel in the fields of medicine dealing with the preparations for and treatment of victims of terror attacks)
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Tertomotide for locally advanced or metastatic pancreatic cancer
2005	NIHR Horizon Scanning Centre (NIHR HSC)	Tesaglitazar for type 2 diabetes and associated lipid abnormalities - horizon scanning review
2011	HAYES, Inc.	testing
2014	NIHR Health Services and Delivery Research programme	Testing accelerated experience-based co-design: a qualitative study of using a national archive of patient experience narrative interviews to promote rapid patient-centred service improvement
2007	Haute Autorite de sante (HAS)	Testing and detection of a lupus anticoagulant
1993	Health Council of the Netherlands Gezondheidsraad (GR)	Testing and prediction
2006	Agency for Healthcare Research and Quality (AHRQ)	Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure
2012	Medical Services Advisory Committee (MSAC)	Testing for BRAF mutation in patients with metastatic melanoma for access to (1c) vemurafenib
2018	Center for Evidence-based Practice (CEP)	Testing for clostridium difficile in oncology patients
2007	Agency for Healthcare Research and Quality (AHRQ)	Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs).
2013	Medical Services Advisory Committee (MSAC)	Testing for epidermal growth factor receptor (EGFR) status in patients with locally advanced (stage IIIB) or metastatic (stage IV) non-small cell lung cancer (NSCLC) for access to erlotinib
2007	Haute Autorite de sante (HAS)	Testing for FV Leiden and FII 20210G>A mutations
2007	Haute Autorite de sante (HAS)	Testing for Heparin-Induced thrombocytopenia
2012	Medical Services Advisory Committee (MSAC)	Testing for HER-2 status in advanced or metastatic breast cancer (stage IIIA-IV) to access lapatinib
2006	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Testing for HER2 positive breast cancer: a cost-effectiveness analysis
2007	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Testing for HER2 positive breast cancer. Challenge for improvement of current conditions and practice
2012	Medical Services Advisory Committee (MSAC)	Testing for HER2 positivity in patients diagnosed with breast cancer to determine eligibility for treatment with trastuzumab
2012	Medical Services Advisory Committee (MSAC)	Testing for HER2 status in gastric cancer for access to trastuzumab
2003	ECRI	Testing for HER2/NEU status in breast cancer
2017	Adelaide Health Technology Assessment (AHTA)	Testing for hereditary mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
2015	Adelaide Health Technology Assessment (AHTA)	Testing for hereditary mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
2023	Ontario Health	Testing for homologous recombination deficiency in patients diagnosed with ovarian cancer
2013	Medical Services Advisory Committee (MSAC)	Testing for V600 status in patients with locally advanced or metastatic melanoma for access to appropriate therapies
2013	Agency for Healthcare Research and Quality (AHRQ)	Testing of CYP2C19 variants and platelet reactivity for guiding antiplatelet treatment
2021	NIHR Health Technology Assessment programme	Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation
2003	Finnish Office for Health Care Technology Assessment (Finohta)	Testing the regional application of information technology (IT) in social welfare and health care (Satakunta Macropilot project)
2005	NIHR Health Technology Assessment programme	Testing treatments on animals: relevance to humans
2014	Health Quality Ontario (HQO)	Testing vitamin B12 levels in neuropathy, alopecia, dizziness, and fatigue: a rapid review
2013	HAYES, Inc.	Testosterone for low sexual desire in nonsurgically postmenopausal women
2009	HAYES, Inc.	Testosterone for low sexual desire in premenopausal women
2009	HAYES, Inc.	Testosterone for low sexual desire in surgically postmenopausal women
2022	Center for Evidence-based Practice (CEP)	Testosterone reference ranges for gender diverse individuals
2002	The Swedish Council on Health Technology Assessment (SBU)	Testosterone replacement in men with age-related hormone deficiency - early assessment briefs (ALERT)
2011	Center for Evidence-based Practice (CEP)	Tests for early diagnosis of sepsis
2022	Norwegian Institute of Public Health (NIPH)	Tests for the detection of NTRK gene fusions in patients with locally advanced or metastatic solid tumours
2003	Health Council of the Netherlands Gezondheidsraad (GR)	Tetanus prophylaxis in injuries
2006	Health Council of the Netherlands Gezondheidsraad (GR)	Tetrachloroethane; Health-based recommended occupational exposure limit
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Texture analysis of Radiological images (TexRAD) for lung cancer assessment
2021	Institute for Clinical and Economic Review (ICER)	Tezepelumab for severe asthma
2014	NIHR Horizon Scanning Centre (NIHR HSC)	TH-302 in combination with doxorubicin for locally advanced or metastatic, unresectable soft tissue sarcoma – first line
1999	ECRI	Thalamic stimulation for Parkinson's disease
1996	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	Thalamic stimulation for tremor treatment (systematic review, primary research, expert panel)
2000	Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ)	Thalamus stimulation for the treatment of pharmacotherapy resistant tremor - primary research
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Thalidomide (Thalidomide Pharmion®) in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged GE 65 years or ineligible for high dose chemotherapy